Mesoblast, an Australia-listed regenerative medicine company, has raised A$170m ($150m) in a private placement of shares including to its “existing strategic investors”.

Under the placement, 27 million ordinary shares, 9.4%, were issued at A$6.30 each, a discount of 2.2% to the closing price of the company’s shares on 1 March. 

However, Mesoblast’s spokeswoman by email said drugs group “Teva did not participate in the placement but retains its current shareholding”.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?